Astellas Pharma, Inc.;TRON-Translationale Onkologie an der Universitatsmedizin der Johannes Gutenberg-Universitat Mainz Gemeinnutzige GmbH
发明人:
SAHIN, Ugur,TURECI, Ozlem
申请号：
AU2020210165
公开号：
AU2020210165A1
申请日:
2020.07.27
申请国别(地区):
AU
年份:
2020
代理人:
摘要：
#$%^&*AU2020210165A120200813.pdf#####ABSTRACT The present invention generally provides a therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, in particular cancer diseases such as gastroesophageal cancer. Data are presented demonstrating that administration of an anti-CLDN18.2 antibody to human patients with gastroesophageal cancer is safe and well-tolerated up to a dose of at least 1000 mg/m2 . Furthermore, data are presented demonstrating that the antibody is fully functional in these patients to execute anti-tumor cell effects and evidence for antitumoral activity was obtained.
